Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

v3.19.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

 

    As of December 31, 2018     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2018  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 3,127     $ 3,127     $ -     $ -     $ 3,127  
Other long-term liabilities:                                        
Warrant liability     360       360       -       -       360  
    $ 3,487     $ 3,487     $ -     $ -     $ 3,487  

  

    As of December 31, 2017     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2017  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 1,581     $ 1,581     $ -     $ -     $ 1,581  
Other long-term liabilities:                                        
Warrant liability     473       473       -       -       473  
    $ 2,054     $ 2,054     $ -     $ -     $ 2,054  

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

                      Cancellation     Adjustment        
                      of Obligation/     to Fair Value/        
    December 31, 2017     Payments (1)     Accretion     Conversions Exercises     Mark to Market     December 31, 2018  
                                     
Asuragen   $ 1,581     $ (307 )   $ 331     $         -     $ 1,522     $ 3,127  
                                                 
Underwriters Warrants     473       -       -       -       (113 )     360  
    $ 2,054     $ (307 )   $ 331     $ -     $ 1,409     $ 3,487  

 

  (1) Royalty payments of $307,000 are reflected within Cash Flows from Operations.